Key points from article :
Frontier Bio has developed a method to produce living human blood vessels in the lab using tissue engineering.
This technology has the potential to reduce or eliminate the reliance on animal testing for vascular medical devices.
Demonstrated a real-world application of its innovation by creating a tissue-engineered blood vessel (TEBV) with an aneurysm.
The company is also developing TEBVs as vascular grafts for implantation into patients.
Company harnesses 3D printing in novel ways to mimic complex vascular structures.
Setting its sights beyond just blood vessels, with plans to engineer neural and lung tissues.
Engineered tissues are likely to make major impacts in the in vitro space in the next few years.
Frontier Bio is paving the way for a future where organ donors are no longer needed, and animal testing is a thing of the past.
